A LinkedIn post from Nabla highlights a physicians roundtable at HIMSS2026 focused on the evolution from “ambient” AI that documents care to “agentic” AI that can act within clinical workflows. The discussion, moderated by Nabla’s chief medical officer and featuring several clinical leaders, examined an emerging “autonomy ladder” for healthcare AI and emphasized governance and trust as key constraints.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post suggests that health systems are already piloting agentic AI in revenue cycle, care coordination, and patient safety workflows, using governance models originally built for ambient AI as a foundation. For investors, this focus on agentic capabilities and robust governance could signal growing demand for more deeply integrated clinical AI tools, potentially expanding Nabla’s addressable market and strengthening its positioning in enterprise health system deployments.
If Nabla can translate thought-leadership visibility at events like HIMSS into commercial relationships, it may benefit from early-mover advantages as hospitals transition from experimentation to operational adoption of AI. However, the emphasis on governance and trust also implies that sales cycles may remain lengthy and that regulatory and compliance requirements could meaningfully influence the pace and scale of monetization in this segment.